Our large urban HIV clinic in Uganda has made concerted efforts to initiate ART at higher CD4 cell counts and to improve diagnosis and care of patients coinfected with tuberculosis (TB). We sought to determine associated treatment outcomes. Routinely collected data for all patients

who initiated ART from 2005 to 2009 were analysed. Median baseline CD4 cell counts by year of ART initiation were compared using the Cuzick test for trend. Mortality and TB incidence rates in the first year of ART were computed. Hazard ratios (HRs) were calculated using multivariable Cox proportional hazards models. First-line ART was initiated in 7659 patients; 64% were women, and the mean age was 37 years (standard deviation 9 years). Median baseline CD4 counts increased from 2005 to 2009 [82 cells/μL (interquartile range (IQR) 24, 153) to 148 cells/μL (IQR 61, 197), respectively; P < 0.001]. The mortality rate fell from 6.5/100 person-years at risk (PYAR) Selumetinib price [95% confidence interval (CI) 5.5–7.6 PYAR] to 3.6/100 PYAR (95% CI 2.2–5.8 PYAR). TB incidence rates increased from 8.2/100 PYAR (95% CI 7.1–9.5 PYAR) to 15.6/100 PYAR (95% CI 12.4–19.7 PYAR). A later

year of ART initiation was independently associated with decreased mortality (HR 0.91; 95% CI 0.83–1.00; P = 0.04). Baseline CD4 cell counts have increased over time and are associated with decreased mortality. Additional reductions in mortality might be a result of a better standard of care and increased TB case finding. Further efforts

to initiate ART earlier should be prioritized even in a setting of capped or reduced Ruxolitinib in vitro funding for ART programmes. The use of antiretroviral therapy (ART) decreases mortality in HIV-infected individuals [1, 2]. In recent years, increasing evidence from resource-rich and resource-limited settings has been published to support initiation of ART at higher baseline CD4+T cell (CD4) count to decrease mortality and morbidity even further [3-7]. ART guidelines both in industrialized countries and in resource-limited settings reflect these data [8]; the World Health Organization (WHO) increased the CD4 count threshold at which ART is to be initiated N-acetylglucosamine-1-phosphate transferase from 200 to 350 cells/μL in their guidelines of December 2009 [9]. CD4 cell counts at ART initiation are often lower in resource-limited settings compared with industrialized countries, and are associated with higher mortality after ART initiation (which is driven by low CD4 cell counts) [10-13]. The higher mortality is ascribed to late presentation of HIV-infected patients to care, but is also attributable to the higher prevalence of opportunistic infections, especially tuberculosis (TB), and limited access to prophylaxis, diagnostic and treatment facilities for these opportunistic infections [11]. Our large urban HIV clinic has made concerted efforts to initiate ART at higher CD4 cell counts and to improve diagnosis and care in patients coinfected with TB.